List view / Grid view
Drug testing on advanced cell-based models such as organoids has gained in popularity, but significant technical hurdles remain that prevent further assay miniaturisation and higher assay throughput. Through the replacement of animal-derived basement membranes with wood-derived nanofibrillar cellulose hydrogel (NFC), Dr Tijmen Booij and Dr Christian Stirnimann from ETH Zurich,…
Here Bio-Rad presents the generation of specific anti-CAR T-cell antibodies to show how CAR T-cell analysis benefits from our modular antibody assembly technology using SpyTag-SpyCatcher protein ligation.
In this section, Dr Peter O’Toole, University of York, examines innovation in the field of microscopy for drug discovery and development research, while in an exclusive Q&A, Dr Michael Grange, Rosalind Franklin Institute, discusses the advantages of utilising cryo-electron tomography imaging.
An easy-to-follow guide to flow cytometry that is well suited for researchers new to the technique, or experienced scientists looking for a refresher.
Podcast discussion featuring CAR-T Cell therapy development and reviewing current challenges and future potentials for these cell therapies.
This guide shows how to reduce cost and time by setting up reproducible HTS/HCS with 3D cell culture models with animal-free GrowDex® hydrogels.
Two new papers from the Human Cell Atlas shed new light on the types and traits of immune cells that can be found in the human body, from developmental stages to adulthood.
9 May 2022 | By PerkinElmer and C4
Looking for a way to address the undruggable proteins in the human body? Watch this free on-demand webinar where industry experts discuss strategies to accelerate TPD drug discovery efforts using high-throughput cell-based assays.
Find out more about the CAR-T cell therapy workflow in this informative infographic from Bio-Rad Laboratories (CA, USA). Discover some of the challenges associated with CAR-T cell R&D as well as technologies and reagents used for bioanalytical analysis.
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
By screening various drugs, a new study has found a childhood leukaemia therapeutic is also efficient in treating bladder cancer.
Read about hydrogels that provide defined and tuneable material properties that allow the controlled inclusion of biochemical cues.
Tune in to this podcast to hear industry experts discuss cell line monoclonality and the emerging methods that can support clonal origin assurance.
The rising number of biologics approved for therapeutic use has placed an emphasis on safe and efficient production lines. Here, Drug Target Review’s Editor Victoria Rees considers why biotherapeutic development is likely to prompt significant growth for the cell line market in the next decade.
Read this bulletin to learn about a Bio-Rad study where they developed and tested a 16-parameter flow cytometry panel applicable to the interrogation of a range of biologically relevant markers of T cell activation.
